Triple threat: immunotherapy and targeted drug join forces against esophageal cancer
NCT ID NCT07457528
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 trial tests whether adding two newer drugs—serplulimab (an immunotherapy) and nimotuzumab (a targeted therapy)—to standard chemoradiation before surgery can improve outcomes for people with resectable esophageal cancer. About 46 participants will receive the combination, then undergo surgery 6–8 weeks later. The main goal is to see if the tumor shrinks significantly (major pathological response) and how safe the regimen is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serplulimab (immunotherapy) and nimotuzumab (targeted therapy) plus chemotherapy and radiation
What this could lead to
If successful, this combination could improve the chance of eliminating the tumor before surgery, potentially leading to better long-term outcomes for esophageal cancer patients.
What could go wrong
This is a small, early-phase trial (46 people) with no control group, so results may not be definitive. Adding multiple drugs to chemoradiation also raises the risk of side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.